Physician profile
Gary R Gize
NPI 1255333167
$4,892.92
in general payments reported to CMS, 2019-2025
47 companies · $2,024 in 2025
The $2,024 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $98.46 · 2021: $444 · 2022: $250 · 2023: $666 · 2024: $968 · 2025: $2,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,669 · Consulting Fee: $900 · Education: $89.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,668.86 |
| Consulting Fee | $900.00 |
| Education | $89.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caris Mpi, INC. | $1,023.32 | 2025 | Mi Cancer Seek |
| Janssen Biotech, INC. | $740.57 | 2019-2025 | Tecvayli, Rybrevant, Carvykti |
| Genentech USA, INC. | $232.34 | 2019-2025 | Tecentriq, Alecensa, Itovebi |
| Genzyme Corporation | $229.09 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $208.98 | 2021-2025 | Enhertu |
| Pfizer INC. | $200.06 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $179.64 | 2022-2025 | Keytruda, Welireg |
| Novartis Pharmaceuticals Corporation | $170.28 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $164.27 | 2023-2025 | Opdivo, Opdualag |
| Regeneron Healthcare Solutions, INC. | $144.62 | 2021-2024 | Libtayo |
| Celgene Corporation | $134.25 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Verastem, INC. | $122.06 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $114.20 | 2022-2023 | Epkinly |
| Abbvie INC. | $110.37 | 2024-2025 | |
| Foundation Medicine, INC. | $98.46 | 2020 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $73.64 | 2023-2025 | Bavencio |
| Takeda Pharmaceuticals U.S.A., INC. | $69.10 | 2019-2024 | Fruzaqla |
| Kite Pharma, INC. | $68.71 | 2021-2025 | Yescarta |
| Alexion Pharmaceuticals, INC. | $62.35 | 2023-2024 | Ultomiris |
| Legend Biotech USA INC. | $59.57 | 2024-2025 | Carvykti |
| Eisai INC. | $50.07 | 2024-2025 | |
| Gilead Sciences, INC. | $46.56 | 2021-2025 | Trodelvy |
| Daiichi Sankyo INC. | $45.68 | 2023-2025 | Enhertu, Injectafer |
| Astellas Pharma US INC | $44.89 | 2025 | Vyloy, Padcev |
| Genmab U.S., INC. | $39.97 | 2023-2024 | Tivdak, Epkinly |
| Tg Therapeutics, INC. | $36.56 | 2022 | |
| Stemline Therapeutics INC. | $35.03 | 2024 | Orserdu |
| Beigene USA, INC. | $33.43 | 2022-2024 | Brukinsa |
| Adaptive Biotechnologies Corporation | $29.74 | 2024 | Clonoseq |
| Ipsen Biopharmaceuticals, INC | $26.55 | 2024 | Tazverik |
| Rigel Pharmaceuticals, INC. | $24.71 | 2023 | Tavalisse, Rezlidhia |
| Novocure INC. | $22.49 | 2024 | Optune Lua (Novottf-200t) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.50 | 2023 | Gilotrif |
| Aveo Pharmaceuticals, INC. | $20.00 | 2025 | |
| Fennec Pharmaceuticals, INC. | $19.34 | 2024 | Pedmark |
| Aadi Bioscience, INC. | $19.18 | 2023 | Fyarro |
| Beone Medicines USA, INC. | $19.12 | 2025 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $19.11 | 2025 | |
| Jazz Pharmaceuticals INC. | $17.38 | 2025 | |
| Seagen INC. | $17.00 | 2022 | |
| Coherus Oncology, INC. | $16.92 | 2025 | Loqtorzi |
| Progenics Pharmaceuticals, INC. | $15.59 | 2025 | |
| Amgen INC. | $15.41 | 2019 | |
| Incyte Corporation | $14.17 | 2025 | Monjuvi |
| Acrotech Biopharma INC. | $13.93 | 2021 | |
| Array Biopharma INC | $12.87 | 2024 | Lorbrena, Mektovi, Braftovi |
| Janssen Pharmaceuticals, INC | $9.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Gize listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.